New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
07:59 EDTPFE, MDT, PRGO, VRX, AGN, ABBV, SHPG, ABT, MYL, AZN, COVTreasury Secretary urges Congress to take action on tax inversions
Treasury Secretary Jack Lew, in a letter to Senate Finance Committee Chairman Ron Wyden and others, urged Congress to take action to address the "urgent issue" of tax inversions, which Lew said "function to hollow out the U.S. corporate income tax base." Lew noted that President Obama proposes to ensure that companies cannot change their tax domicile without a change in control of the company. According to Lew, several senators have "put companies on notice that any transaction that takes place after early May will not have the desired effect of lowering future U.S. tax liabilities." Tax inversions are a particularly significant issue in the pharmaceutical industry. Companies that have recently proposed transactions that involve an inversion component or have been linked to potential transactions include Pfizer (PFE), AstraZeneca (AZN), Mylan (MYL), Abbott (ABT), Shire (SHPG), AbbVie (ABBV), Allergan (AGN), Valeant (VRX), Perrigo (PRGO), Medtronic (MDT) and Covidien (COV). Reference Link
News For PFE;AZN;MYL;ABT;SHPG;ABBV;AGN;VRX;PRGO;MDT;COV From The Last 14 Days
Check below for free stories on PFE;AZN;MYL;ABT;SHPG;ABBV;AGN;VRX;PRGO;MDT;COV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
August 7, 2014
06:34 EDTMYLMylan reports Q2 adjusted EPS 69c, consensus 70c
Reports Q2 revenue $1.84B, consensus $1.88B.
06:13 EDTAZNDynavax says AZD1419 Phase 1 study met secondary endpoints
Subscribe for More Information
August 6, 2014
17:18 EDTVRX, AGNPershing files Valeant confidentiality pact with SEC
Subscribe for More Information
15:49 EDTMYLNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Duke Energy (DUK), consensus 98c; Intercontinental Exchange (ICE), consensus $2.02; Mylan (MYL), consensus 70c; Scripps Networks (SNI), consensus $1.13; Brinker International (EAT), consensus 87; AES Corporation (AES), consensus 28c; NRG Energy (NRG), consensus 15c; Harman International (HAR), consensus $1.21; Windstream Holdings (WIN), consensus 8c; Teradata (TDC), consensus 65c; Markel (MKL), consensus $5.79; OGE Energy (OGE), consensus 51c; SunEdison (SUNE), consensus (28c); Royal Gold (RGLD), consensus 29c; Sabre (SABR), consensus 18c; Broadridge (BR), consensus $1.16; Huntington Ingalls (HII), consensus $1.81; AMC Networks (AMCX), consensus 85c; Laredo Petroleum (LPI), consensus 18c; HSN (HSNI), 77c; Wendy's (WEN), consensus 10c; Orbitz Worldwide (OWW), consensus 15c.
15:17 EDTVRX, AGNValeant, Pershing comment on ISS recommendation in favor of Allergan meeting
Subscribe for More Information
13:42 EDTCOV, MDTMedtronic says approval for Covidien deal 'progressing'
Subscribe for More Information
13:39 EDTMDT, COVMedtronic CEO says Covidien deal should close end of year, early next
Subscribe for More Information
13:38 EDTMDT, COVMedtronic CEO says 'progressing' in Covidien deal approval process
Subscribe for More Information
12:59 EDTABBV, COV, MDT, SHPGCovidien drops as Treasury explores ways to stymie inversions
Shares of medical device and drug maker Covidien (COV) are falling after multiple media outlets reported that the Treasury Department is looking into ways of curtailing tax inversion deals. Covidien has agreed to be acquired by Medtronic (MDT) in a tax inversion deal. BACKGROUND: Tax inversions refer to an acquisition of one company, usually officially based in a country in Europe or elsewhere, by a U.S. company, following which the acquiring company becomes domiciled in the same country as the company that it bought. The switch has the potential to significantly lower the acquiring company's tax rate. WHAT'S NEW: The Treasury Department is looking at options that would enable the Obama administration to curtail inversion deals without authorization from Congress, multiple media outlets reported last night and today. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that he believes that Medtronic would buy Covidien even if the transaction cannot be done as an inversion. At a conference in June, Medtronic CFO Gary Ellis said that his company would "do the deal whether it's an inversion or not inversion," Biegelsen stated. If no inversion is possible, Medtronic would respond by using less of its stock and more debt to fund the transaction, the analyst believes. Such a change would actually cause Medtronic's cash earnings per share to be higher in the first and second year after the deal than under the current structure, the analyst indicated. He kept an Outperform rating on Medtronic. PRICE ACTION: In early afternoon trading, Covidien dropped 2% to $84.50 and Medtronic fell 1% to $61.50. Meanwhile, drug maker Shire (SHPG), which has agreed to merge with its peer AbbVie (ABBV) in a tax inversion deal, is falling 4% to $236.
12:57 EDTVRX, AGNAllergan says proxy recommendations don't change inadequacy of Valeant offer
Subscribe for More Information
12:20 EDTMDT, COVMedtronic remains committed to Covidien deal, says Wells Fargo
Following recent conversations with the company, Wells Fargo believes Medtronic (MDT) remains committed to the acquisition Covidien (COV), even if the deal can't be structured as an inversion. The firm notes that at its conference in June, Medtronic CFO Gary Ellis stated that "from Medtronic's perspective, we would do the deal whether it's an inversion or not inversion." Wells adds, however, that Medtronic would likely try to renegotiate the terms of the deal if an inversion is not possible.
12:10 EDTPFEPfizer settles multi-state complaint on improper promotion of Rapamune
Attorney General Eric T. Schneiderman announced that he, along with 40 other state Attorneys General and the District of Columbia, reached a $35M settlement with Pfizer arising from alleged improper marketing and promotion of the immunosuppressive drug Rapamune. New York’s share of the settlement is over $1.7M. Pfizer, as parent of Wyeth Pharmaceuticals, agrees to be bound by the judgment and to resolve allegations that Wyeth unlawfully promoted Rapamune. Attorney General Schneiderman’s office served on the Executive Committee of this multi-state investigation. Reference Link
11:10 EDTAGNOptions with increasing implied volatility
Subscribe for More Information
09:19 EDTSHPG, AZNShire, AstraZeneca, Smith & Nephew slump amid inversion fears, FT says
Subscribe for More Information
09:13 EDTSHPGOn The Fly: Pre-market Movers
HIGHER: Fox class A shares (FOXA), up 5.9% after withdrawing proposal to acquire Time Warner (TWX), announcing $6B share repurchase program, reporting quarterly results... MannKind (MNKD), up 1.6% after entering a supply agreement with Amphastar Pharmaceuticals (AMPH)... Criteo (CRTO), up 11.5% after upgraded at Goldman following its better than expected Q2 earnings report. LOWER: Time Warner (TWX), down 13% after earnings, maintaining guidance, bid dropped by Fox... Sprint (S), down 16.5% after naming Marcelo Claure as president and CEO, reportedly dropping pursuit of T-Mobile (TMUS). T-Mobile shares also down 8.5%... Groupon (GRPN), down 18%, downgraded at Wunderlich after the company reported lower than expected Q3 results... Walgreen (WAG), down 15.7% after exercises option to acquire remaining 55% of Alliance Boots, says it will not pursue inversion as part of deal... Shire (SHPG), down 6% after Walgreen announced it would stay located in Chicago and Bloomberg last night reported that the Treasury Department is exploring ways to bypass Congress in an attempt to curb corporate inversions... Cytori Therapeutics (CYTX), down 33% after announcing that it has placed enrollment in the ATHENA and ATHENA II trials on clinical hold. UP AFTER EARNINGS: Enphase Energy (ENPH), up 20%... AOL (AOL), up 5%. DOWN AFTER EARNINGS: Nu Skin (NUS), down 8.5%... Rocket Fuel (FUEL), down 27%... Cognizant (CTSH), down 13%... First Solar (FSLR), down 2.5%... Globus Medical (GMED), down 17%.
08:40 EDTSHPG, ABBVShire drops 5% with tax inversions in focus
Subscribe for More Information
07:21 EDTAGN, VRXValeant recent weakness a buying opportunity, says JPMorgan
JPMorgan recommends using the recent pullback in shares of Valeant (VRX) as a buying opportunity. After meeting with management, the firm has increased confidence in the company's ability to show accelerating top-line growth in the second half of 2014. It sees "compelling value" in Valeant shares regardless of the Allergan (AGN) outcome and keeps an Overweight rating on the stock with a $180 price target.
06:41 EDTMDT, MYL, ABT, VRX, COVObama administration may restrict inversion tax benefits, NY Times says
Subscribe for More Information
06:23 EDTPFEMitsubishi UFJ to hold a conference
Subscribe for More Information
06:21 EDTPFE, MDTPiper Jaffray to hold a summit
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use